Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Gross Margin (2020 - 2025)

Historic Gross Margin for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to 53.46%.

  • Insight Molecular Diagnostics' Gross Margin rose 99800.0% to 53.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 54.73%, marking a year-over-year increase of 507800.0%. This contributed to the annual value of 39.34% for FY2024, which is 118600.0% up from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' Gross Margin stood at 53.46%, which was up 99800.0% from 67.57% recorded in Q2 2025.
  • Insight Molecular Diagnostics' Gross Margin's 5-year high stood at 72.47% during Q4 2021, with a 5-year trough of 401.49% in Q3 2022.
  • Over the past 5 years, Insight Molecular Diagnostics' median Gross Margin value was 25.57% (recorded in 2024), while the average stood at 2.15%.
  • In the last 5 years, Insight Molecular Diagnostics' Gross Margin soared by 92195300bps in 2021 and then plummeted by -3134800bps in 2022.
  • Insight Molecular Diagnostics' Gross Margin (Quarter) stood at 72.47% in 2021, then tumbled by -114bps to 9.85% in 2022, then plummeted by -278bps to 37.26% in 2023, then surged by 207bps to 40.04% in 2024, then skyrocketed by 34bps to 53.46% in 2025.
  • Its last three reported values are 53.46% in Q3 2025, 67.57% for Q2 2025, and 61.97% during Q1 2025.